Treatment with 177Lutetium-DOTA-Tyr3-octreotate in Patients with Neuroendocrine Tumors

#178

Introduction: Neuroendocrine tumors express somatostatin receptors. Treatment with radiolabelled somatostatin analogs has been used for more than 10 years. Useful isotopes are 111Indium, 99Yttrium and 177Lutetium.

Aim(s): To report our experience with 177Lutetium-DOTA-Tyr3-octreotate in patients with malignant neuroendocrine tumors.

Materials and methods: Two-hundred and thirty-one patients; 96 midgut, 13 lung, 18 rectal, 44 non-functioning EPT, nine gastrinomas, six glucagonomas, two insulinomas, eight pheo/paragangliomas, 35 other, have each received 1–8 treatments, decided by dosimetry, with 6–12 weeks’ interval. Almost all progressed on prior therapy. One-hundred and ninety patients were evaluated with CT/MRI. Mean follow-up was 13.3 months (2–57).

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Granberg D, Sandström M, Sundin A, Welin S, Kozlovacki G,

Keywords: NETs, Lutetium, radiolabelled somatostatin analogs, PRRT,